Cognito Therapeutics, which is in late-stage development of its device to treat neurodegenerative diseases like Alzheimer’s, hauled in $105 million in an oversubscribed series C funding round. The ...

Gamma oscillations, brain activity needed for sensory processing, cognition and memory consolidation, are disrupted in Alzheimer’s. Research in mice suggests evoking the oscillations with light and ...

Cognito Therapeutics, a company using visual and auditory stimulation to treat neurodegenerative disorders, announced it closed an oversubscribed $105 million Series C funding round. Morningside ...

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

Series C proceeds position Spectris for pivotal top-line data, regulatory submission, and launch planning ahead of a targeted 2027 U.S. market entry. Spectris delivers coordinated visual and auditory ...

Cognito Therapeutics, a Cambridge neurotech startup, has locked in a $105 million financing round to drive its at-home Alzheimer’s therapy toward an FDA submission. The cash infusion lands just as the ...

Amazon Web Services surpassed Wall Street expectations on revenue and operating income. AWS' operating margin widened slightly to 35% in the fourth quarter from 34.6% in the prior period. Amazon plans ...

Amazon Web Services’ annual tech conference AWS re:Invent has wrapped. And the singular message, amid a deluge of product news and keynotes, was AI for the enterprise. This year it was all about ...

The Spectris non-invasive neuromodulation system. [Image courtesy of Cognito Therapeutics] Cognito Therapeutics and the West Virginia University Rockefeller Neuroscience Institute (RNI) today ...

Katie is a UK-based news reporter and features writer. Officially, she is CNET's European correspondent, covering tech policy and Big Tech in the EU and UK. Unofficially, she serves as CNET's Taylor ...